Skip to main content

Utilization of Ibrexafungerp in Pregnant Patients: An Updated Descriptive Analysis in TriNetX

Basic Details
Date Posted
Status
Complete
Medical Product
ibrexafungerp
Description

This query is part of ongoing active monitoring activities for ibrexafungerp. This query aims to identify early signaling of ibrexafungerp use in pregnant patients.

The study period includes data from June 1, 2020 to December 22, 2022 and contains data from 75 health care organizations (HCOs), provided through the TriNetX Live™ platform in their USA Network. We ran this query on January 19, 2023.

Deliverables (1)
Sentinel Modular Program Report: Utilization of Ibrexafungerp in Pregnant Patients: An Updated Descriptive Analysis in TriNetX
Additional Details
FDA Center
CDER
Time Period
June 1, 2020 – December 22, 2022
Analysis Type
TriNetX Analysis
Population / Cohort
Females 15 years of age and older
Data Sources
TriNetX USA Network
Related Links
Sentinel Drug Study: Brexafemme (Ibrexafungerp) & Use in Pregnancy
TriNetX Rapid Querying